You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CLL

Showing 51 - 75 of 1,319
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML Trial in Hangzhou (CLL1+CD33 CAR-T)

Not yet recruiting
  • AML
  • CLL1+CD33 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 19, 2022

Leukemia, Lymphoma Trial in Houston (Rituximab, Lenalidomide)

Active, not recruiting
  • Leukemia
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 11, 2022

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) Trial run by the National Heart, Lung, and Blood Institute

Active, not recruiting
Has Results
  • Small Lymphocytic Lymphoma
  • CLL (Chronic Lymphocytic Leukemia)
  • Fludarabine Phosphate
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022

Retention Rate of Acalabrutinib in a Non-interventional Setting

Recruiting
  • Chronic Lymphocytic Leukaemia (CLL)
    • Zittau, Germany
      Research Site
    Jan 12, 2023

    Chronic Lymphocytic Leukemia, CLL/SLL Trial in New York (Acalabrutinib)

    Withdrawn
    • Chronic Lymphocytic Leukemia
    • CLL/SLL
    • New York, New York
      Weill Cornell Medicine
    Mar 25, 2022

    Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Ibrutinib and obinutuzumab
    • Milano, MI, Italy
      Strategic Research Program on CLL
    Apr 2, 2022

    Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)

    Completed
    Has Results
    • Hepatitis
    • Safety and Tolerability
    • HEPLISAV-B
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 13, 2022

    T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)

    Not yet recruiting
    • T-cell Lymphoma
    • CLL/SLL
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Aug 11, 2023

    Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Zanubrutinib)

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • Small Lymphocytic Lymphoma
    • Boston, Massachusetts
    • +2 more
    Mar 16, 2022

    Chronic Lymphocytic Leukemia Trial in Madison ([U-13C]glucose, [13C5]glutamine)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • [U-13C]glucose
    • [13C5]glutamine
    • Madison, Wisconsin
      University of Wisconsin
    Jun 15, 2022

    Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)

    Recruiting
    • Acute Myeloid Leukemia
    • Anti-CLL1 CART cells
    • Kunming, Yunnan, China
      No.212 Daguan Road, Xishan District
    Nov 23, 2022

    Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Durham (Myeloma Coach or CLL Coach Mobile App, Springboard Beyond Cancer

    Completed
    • Multiple Myeloma
    • Chronic Lymphocytic Leukemia
    • Myeloma Coach or CLL Coach Mobile App
    • Springboard Beyond Cancer informational website
    • Durham, North Carolina
      Duke University
    Jun 23, 2023

    Chronic Lymphocytic Leukemia (CLL) Trial in United States (Venetoclax, Obinutuzumab, Acalabrutinib)

    Active, not recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • Stamford, Connecticut
    • +4 more
    Dec 2, 2022

    Leukemia Trial in Houston (Pirtobrutinib, Obinutuzumab, Venetoclax)

    Not yet recruiting
    • Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 7, 2022

    Biomarker for Infection Risk in CLL and MM

    Not yet recruiting
    • Multiple Myeloma
    • Chronic Lymphocytic Leukemia
    • Screening
    • Boston, Massachusetts
      Massachusetts General Hospital Cancer Center
    May 3, 2023

    REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

    Not yet recruiting
    • CLL, Relapsed
    • +3 more
      • Clermont-Ferrand, France
      • +7 more
      Nov 16, 2022

      Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)

      Not yet recruiting
      • Chronic Lymphocytic Leukemia
      • (no location specified)
      Jul 10, 2023

      B Cell NHL, CLL Trial in Sydney, Melbourne, Mount Pleasant (GB261)

      Recruiting
      • B Cell NHL
      • CLL
      • GB261
      • Sydney, New South Wales, Australia
      • +4 more
      Nov 16, 2022

      Chronic Lymphocytic Leukemia Trial (Venetoclax)

      Not yet recruiting
      • Chronic Lymphocytic Leukemia
      • (no location specified)
      Apr 2, 2022

      Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) Trial in United States (Zanubrutinib, Obinutuzumab,

      Recruiting
      • Chronic Lymphocytic Leukemia (CLL)
      • Small Lymphocytic Leukemia (SLL)
      • Evanston, Illinois
      • +7 more
      Sep 9, 2022

      Orelabrutinib in Treatment of Chronic Lymphocytic Leukemia/Small

      Recruiting
      • CLL/SLL
      • Jinan, Shandong, China
        Department of Hematology, Shandong Provincial Hospital Affiliate
      Jun 16, 2023

      Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)

      Completed
      • Chronic Lymphocytic Leukemia
      • BNC105P
      • Ibrutinib
      • Lebanon, New Hampshire
        Dartmouth-Hitchcock Medical Center
      Jan 3, 2023

      Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell Trial in Whittier (Pirtobrutinib, Ibrutinib)

      Recruiting
      • Chronic Lymphocytic Leukemia
      • +3 more
      • Whittier, California
        Innovative Clinical Research Institute
      Aug 8, 2022

      Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell Trial (ONO-7018)

      Not yet recruiting
      • Lymphoma, Non-Hodgkin
      • Leukemia, Lymphocytic, Chronic, B-Cell
      • (no location specified)
      Aug 23, 2022